Summit Therapeutics

SUMMIT THERAPEUTICS INC

Summit Therapeutics Inc is a biopharmaceutical company that focuses on the discovery, development, and commercialization of novel antibiotics for serious infectious diseases. Its CDI (Clostridiodes difficile infection) product candidate is ridinilazole, an orally administered small molecule antibiotic. It has two geographical segments: the United States and the United Kingdom.

bz_pharma_briefs

Analyst Color

Biotech

Large Cap

News

Health Care

Initiation

Analyst Ratings

Movers

Trading Ideas

General

SMMT

Summit Therapeutics&#39; ivonescimab shows strong efficacy in trials, with Cantor Fitzgerald predicting a 50% market share in the $100B VEGF x PD-(L)1 space.

Analyst Initiates Coverage On &#39;Undervalued&#39; Summit Therapeutics

Intel's Setbacks

Equities

INTC

PYRGF

RBRK

SMCI

Top 10 large-cap stocks rose last week: Rubrik 23.17%, Applovin 17.21%, Summit Therapeutics 16.93%, Intel 16.52%, VG 16.03%, GE Vernova 14.01%, Samsara 11.96%, Antero Resources 11.68%, Super Micro 10.28%, ConocoPhillips 9.18%

Applovin, Super Micro Computer And Intel Among Top 10 Large-Cap Gainers Last Week (Mar 10-Mar 14): Are The Others In Your Portfolio?

Analysts

Markets

AVTX

CSGP

MDWD

This CoStar Group Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday

Summit Therapeutics Inc

Press Releases

Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Summit Therapeutics to Host Fourth Quarter and Full Year 2024 Financial Results & Operational Progress Call on February 24, 2025

Summit Therapeutics Announces Clinical Trial Collaboration with Pfizer to Evaluate Ivonescimab in Combination with Pfizer Antibody Drug Conjugates (ADCs)

Summit Therapeutics Reports Financial Results and Operational Progress for the Fourth Quarter and Twelve Months Ended December 31, 2024

Akeso Highlights Collaboration Between Its Partner Summit Therapeutics and Pfizer to Explore Ivonescimab in Combination with Pfizer's ADCs

Coeptis Inc. (COEP) Expands Cancer Immunotherapy Portfolio with Exclusive GEAR Cell Therapy License

Robert LaCaze, Innovative Growth-Driver in Oncology, Joins Summit Therapeutics as Chief Commercial Officer

ALNY

COEP

REGN

RPRX

VRTX

AbbVie

Alnylam Pharmaceuticals, Inc. - Common Stock

Alnylam Pharmaceuticals

Amgen

argenx

Ascendis Pharma A/S - American Depositary Shares

Ascendis Pharma

Biogen

BioMarin Pharmaceutical Inc. - Common Stock

Biomarin Pharmaceutical

BioNTech

Exact Sciences Corporation - Common Stock

Exact Sciences

Exelixis

Gilead Sciences

Genmab

Halozyme Therapeutics, Inc. - Common Stock

Halozyme Therapeutics

Incyte

Insmed

Madrigal Pharmaceuticals, Inc. - Common Stock

Madrigal Pharmaceuticals

Moderna

Neurocrine Biosciences, Inc. - Common Stock

Neurocrine Biosciences

Natera

BeiGene, Ltd. - American Depositary Shares

BeiGene

Vaxcyte

Regeneron Pharmaceuticals, Inc. - Common Stock

Regeneron Pharmaceuticals

Roivant Sciences

United Therapeutics Corporation - Common Stock

United Therapeutics

Vertex Pharmaceuticals Incorporated - Common Stock

Vertex Pharmaceuticals

Evercore ISI Group

Goldman Sachs

Citizens Capital Markets

HC Wainwright & Co.

Truist Securities

Comments

Summit Therapeutics

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga